An expert from Seattle Cancer Care Alliance highlights key skills in nurse navigation.
Confidence and oncology knowledge are crucial skills for effective nurse navigators, according to Janelle Wagner, RN, OCN.
In an interview with Oncology Nursing News®, Wagner, senior manager of Patient Navigation Program for Community Sites, Seattle Cancer Care Alliance, explained what skills are necessary for an oncology nurse to become an effective nurse navigator and offered advice for any prospective navigators seeking a career shift.
“Being a nurse navigator requires somebody who has a broad understanding of oncology care. [This is someone] who has worked in many different aspects of oncology, from inpatient to infusion to the clinic, [experience with] radiation oncology is helpful, [as well as] surgical oncology. Someone who understands the bigger picture of how all aspects of care happen—rather than just one discipline.”
“In terms of implementation, it's really bringing a full team together. When looking at oncology care, you're looking at multiple disciplines: surgical oncology, medical oncology, radiation oncology, etc. It’s really [about] bringing that whole team together to see what the current state is. How do the patients currently flow through the system? Is it working? Where are the gaps; where does the patient get kind of lost in the system? How can the nurse navigator be that person to help? Again, it's working with the existing system to hold that patient's hand and get them in to the right places and the right timeframe.”
Tucatinib Continues to Show Benefit in Pretreated HER2+ Breast Cancer With Brain Metastases
December 7th 2023The primary analysis of the phase 3 HER2CLIMB-02 demonstrates that tucatinib slowed disease progression in patients with HER2-positive metastatic breast cancer, including those with brain metastases.
Tucatinib Continues to Show Benefit in Pretreated HER2+ Breast Cancer With Brain Metastases
December 7th 2023The primary analysis of the phase 3 HER2CLIMB-02 demonstrates that tucatinib slowed disease progression in patients with HER2-positive metastatic breast cancer, including those with brain metastases.
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
Tucatinib Continues to Show Benefit in Pretreated HER2+ Breast Cancer With Brain Metastases
Ribociclib Plus Endocrine Therapy Continues to Perform Well Across MONALEESA-2, -3, and -7 Trials
Patient-Reported Outcomes From CAPItello-291 Trial Support Capivasertib/Fulvestrant in HR+, HER2- Advanced Breast Cancer
2 Clarke Drive
Cranbury, NJ 08512